{
  "docId": "019de072-50fd-76be-bc50-13d10a429187",
  "docSlug": "745181b5445c8f31a0d7e29e54da559e",
  "documentTitle": "Chimerix | Results Presentation Deck | 12 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 12,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_messages",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a split-panel comparison format to bridge previous development (norovirus) with current application (SARS-CoV-2).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-50fd-76be-bc50-13d10a429187/4",
  "deckHref": "/decks/019de072-50fd-76be-bc50-13d10a429187",
  "deckJsonHref": "/decks/019de072-50fd-76be-bc50-13d10a429187.json",
  "deckAnchorHref": "/decks/019de072-50fd-76be-bc50-13d10a429187#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.42,
        "x": 0.51,
        "y": 0.33
      },
      "kind": "list",
      "text": "Low µM in vitro activity across diverse coronaviruses; In vivo efficacy in SARS-CoV-2-MA10 mouse-model; Inhalation administration maximizes respiratory exposure; Primed for rapid development to clinical POC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66b44861-dc17-4ff9-95ba-44adb682d491",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.42,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "list",
      "text": "Ribonucleoside triphosphate inhibits norovirus RdRp; Oral formulation developed through Phase I; Excellent safety profile in GLP tox studies; No significant inhibition of human DNA polymerase; Well-tolerated in healthy volunteer Phase I study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79f61e53-66c2-4c1b-9589-1c7ab3de8a08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.06,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "*Confirmation in SARS-CoV-2 RdRp ongoing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c09591c7-8c3a-4a55-bb37-db3a93453acd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.84,
        "x": 0.08,
        "y": 0.03
      },
      "kind": "title",
      "text": "CMX521: Direct-acting antiviral delivered to key site of viral replication to enhance efficacy and safety",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8931ab4-5f57-4a78-8876-bdb4d645a16e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "06f2e26a-b718-46bd-8455-10a94ef7d905",
      "evidence": "list/bullet: Ribonucleoside triphosphate inhibits norovirus RdRp",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "2eaafc1e-e75f-4f3d-a2e6-99103ddc36c1",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the need for effective treatment by presenting key messages on CMX521",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "70334537-1440-402b-83ae-8ddd527abfff",
      "evidence": "The document presents the problem of novel coronavirus outbreaks and the need for effective treatment",
      "position": 0,
      "objective": "Highlight the cost of inaction in treating SARS-CoV-2",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}